MedTrace Logo

Improving Therapeutic Learning in Depression: Proof of Concept

NCT02376257 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 36

Last updated 2018-09-19

Study results available
· View outcomes & findings →

Summary

Despite advances in both pharmacotherapy and psychotherapy for major depression, non-response and partial-response remain relatively common outcomes, motivating the search for new treatments. This study is concerned with the development of one such novel treatment, the augmentation of exposure-based cognitive-behavior therapy (CBT) with d-cycloserine (DCS).

Conditions

Interventions

DRUG

250 mg DCS

Drug

DRUG

100 mg Modafinil

Drug

DRUG

Placebo

Drug

Sponsors & Collaborators

  • Boston University Charles River Campus

    lead OTHER

Principal Investigators

  • Michael W Otto, Ph. D · Boston University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-09-16
Primary Completion
2017-04-21
Completion
2017-05-31
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02376257 on ClinicalTrials.gov